Letters to the Editor
We read with great interest the article by Al-Jammali and colleagues (June 2019 issue), which discussed the challenges associated with the use of anticoagulants for patients who have atrial fibrillation after starting treatment with ibrutinib. We believe that this topic is very timely, given the widespread use of ibrutinib in clinical practice; however, we would like to raise some concerns.
Impact of Pharmacists’ Intervention in Altering Prescribing Patterns for the Treatment of VTE in Patients with Cancer
My student and I have read the above article with much interest. It has led to much research this afternoon and reading of the American College of Chest Physicians (ACCP) 2012 guidelines for confirmation of some of the statements within the article. We would like to point out 2 items.
Results 1 - 2 of 2